

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

**ANNOUNCEMENT
CHANGE OF A NON-EXECUTIVE DIRECTOR**

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of InnoCare Pharma Limited (the “**Company**”) announces that Mr. Quanhong Yuan (“**Mr. Yuan**”) has resigned as a non-executive Director with effect from March 31, 2022 due to his other personal commitments which require more of his dedication and time commitment. Mr. Yuan has confirmed that he has no disagreement with the Board and there are no matters in respect of his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Yuan for his valuable contributions as a non-executive Director to the Company during his tenure of office.

APPOINTMENT OF A NON-EXECUTIVE DIRECTOR

The Board further announces that Mr. Ming Jin (“**Mr. Jin**”), who currently serves as a partner in Beijing Hankang Venture Capital Management Co., Ltd. (北京漢康創業投資管理有限公司) (“**Hankang Capital**”), has been appointed as a non-executive Director with effect from March 31, 2022.

The biographical details of Mr. Jin are set out below:

Mr. Jin, aged 48, has 20 years of experience in the pharmaceutical industry and biotechnology industry and 7 years of investment experience. From August 2000 to June 2004, he worked at Shanghai Sunway Biotech Co., Ltd.. From July 2004 to April 2012, he worked at Tianjin Greenbio Material Co., Ltd.. From May 2012 to June 2017, Mr. Jin worked at Hangzhou Converd Co., Ltd. (杭州康萬達醫藥科技有限公司). He has been an investment director of Hankang Capital since 2017 and was promoted to managing director and partner thereof in 2018 and 2020, respectively.

He obtained a bachelor’s degree in biological science from Zhejiang University, the People’s Republic of China in 1997 and a master’s degree in genetics from the Academy of Military Medical Sciences (軍事醫學科學院), the People’s Republic of China in 2000, respectively.

Pursuant to the service agreement entered into between Mr. Jin and the Company, Mr. Jin is appointed as a non-executive Director with effect from March 31, 2022, for a term of three years. His appointment shall be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Mr. Jin will not receive any remuneration from the Company in relation to his appointment as a non-executive Director.

Save as disclosed above, Mr. Jin does not hold any other position with the Company or its subsidiaries, has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years prior to the date of his appointment and does not have other major appointments and professional qualifications.

Save as disclosed above, to the best knowledge of the Company, Mr. Jin does not have any relationship with any other director, senior management, substantial shareholder or controlling shareholder of the Company, and does not have any interests in the shares in the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) as at the date of this announcement.

Save as disclosed above, there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange, nor are there any other matters, relating to the appointment of Mr. Jin that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Jin in joining the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and executive Director

Hong Kong, 31 March 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Shan Fu, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Dr. Zemin Zhang, Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.